Narendra D. Lalwani, Chief Operating Officer at Esperion Therapeutics, Inc. (ESPR), bought 5,000 shares at $9.93 ($50K) on 2016-11-01, disclosed to the SEC on 2016-11-03.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.